NasdaqGS:CDXSLife Sciences
Codexis (CDXS) Is Up 30.9% After Merck-Fueled Q4 Profit Beat And 2026 Revenue Guidance - Has The Bull Case Changed?
In March 2026, Codexis reported fourth-quarter 2025 results showing revenue of US$38.92 million and net income of US$9.6 million, reversing a prior-year loss and beating analyst expectations, alongside full-year 2025 revenue of US$70.39 million and guidance for 2026 revenue of US$72 million to US$76 million.
The quarter was heavily influenced by a large technology transfer agreement with Merck and growing ECO Synthesis platform activity, which also underpins management’s view that existing...